Shaojie Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shaojie Yang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Jing Kong
Biliary Surgery (2nd General) Unit, Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
1 shared publication - Liwei Pang
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
1 shared publication Lufang Wang
Department of Gynecology, The First Affiliated Hospital of China Medical University, China Medical University, Shenyang, Liaoning, P.R. China
1 shared publication- Shiyuan Bi
Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
1 shared publication - Shuo-Dong Wu
Department of Biliary and Vascular Surgery, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication Siyu Dong
Department of Gynecology, The First Affiliated Hospital of China Medical University, China Medical University, Shenyang, Liaoning, P.R. China
1 shared publication
Latest Publications
- Open Access
- 8 June 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. Publish Ah (7) , 2025-2036
Effectiveness and safety of central pancreatectomy in benign or low-grade malignant pancreatic body lesions: a systematic review and meta-analysis
Background: The best approach for treating benign or low-grade malignant lesions localized in the pancreatic neck or body remains debatable. Conventional pancreatoduodenectomy and distal pancreatectomy (DP) are associated with a risk of impairment of pancreatic function at long-term follow-up. With advances in technology and surgical skills, the use of central pancreatectomy (CP) has gradually increased. Objectives: To compare the safety, feasibility, and short-term and long-term clinical benefits of CP and DP in matched cases. Methods: The PubMed, MEDLINE, Web of Science, Cochrane, and EMBASE databases were systematically searched to identify studies published from database inception to February 2022 that compared CP and DP. This meta-analysis was performed using R software. Results: Twenty-six studies matched the selection criteria, including 774 CP and 1713 DP cases. CP was associated with significantly higher rates of operative time (PPPPP=0.0196), delayed gastric emptying (P=0.0096), hospital stay (PPPPP<0.0001) than DP. Conclusions: CP should be considered as an alternative to DP in selected cases such as without pancreatic disease, length of the residual distal pancreas ≥5 cm, branch-duct IPMNs, and a low risk of POPF after adequate evaluation.
- 8 June 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. Publish Ah (7) , 2025-2036
Open AccessEffectiveness and safety of central pancreatectomy in benign or low-grade malignant pancreatic body lesions: a systematic review and meta-analysis
Background: The best approach for treating benign or low-grade malignant lesions localized in the pancreatic neck or body remains debatable. Conventional pancreatoduodenectomy and distal pancreatectomy (DP) are associated with a risk of impairment of pancreatic function at long-term follow-up. With advances in technology and surgical skills, the use of central pancreatectomy (CP) has gradually increased. Objectives: To compare the safety, feasibility, and short-term and long-term clinical benefits of CP and DP in matched cases. Methods: The PubMed, MEDLINE, Web of Science, Cochrane, and EMBASE databases were systematically searched to identify studies published from database inception to February 2022 that compared CP and DP. This meta-analysis was performed using R software. Results: Twenty-six studies matched the selection criteria, including 774 CP and 1713 DP cases. CP was associated with significantly higher rates of operative time (PPPPP=0.0196), delayed gastric emptying (P=0.0096), hospital stay (PPPPP<0.0001) than DP. Conclusions: CP should be considered as an alternative to DP in selected cases such as without pancreatic disease, length of the residual distal pancreas ≥5 cm, branch-duct IPMNs, and a low risk of POPF after adequate evaluation.
- 7 December 2018
- Published by Wiley in Dermatologic Therapy
- Vol. 32 (4) , e12802
Astragaloside IV inhibits cell proliferation in vulvar squamous cell carcinoma through the TGF‐β/Smad signaling pathway
Objective To explore the inhibition of the proliferation of vulvar squamous cell carcinoma (VSCC) by astragaloside IV. Methods MTT examined the cell proliferation of VSCC. Flow cytometry analyzed cell cycle and apoptosis. Western blot assay detected the expression of some relevant proteins. Results AS‐IV reduced the proliferation of SW962 cells in a concentration‐ and time‐dependent manner, induced cell‐cycle arresting in G0/G1 phase, as demonstrated by the up‐regulation of P53 and P21 expression, and the down‐regulation of cyclin D1 expression. AS‐IV enhanced the expression of Bax and cleaved‐caspase 3, and suppressed Bcl‐2 and Bcl‐xl expression, which resulted in apoptosis increased. Furthermore, the expression of Beclin‐1 and LC3‐B was upregulated and that of P62 was downregulated, which suggested that AS‐IV could increase the incidence of autophagy in SW962 cells. After inhibiting autophagy by 3‐methyladenine, cell apoptosis decreased upon AS‐IV treatment. Similarly, TGF‐β1 stimulated SW962 cells, cell proliferation enhanced, and the expression of TGF‐βRII and Smad4 was decreased. Furthermore, the expression of proteins that promote apoptosis and autophagy decreased. After AS‐IV treatment, the expression levels of the above proteins exhibited the opposite effect. Conclusion AS‐IV inhibits cell proliferation and induces apoptosis and autophagy through the TGF‐β/Smad signaling pathway in VSCC.
- 7 December 2018
- Published by Wiley in Dermatologic Therapy
- Vol. 32 (4) , e12802
Astragaloside IV inhibits cell proliferation in vulvar squamous cell carcinoma through the TGF‐β/Smad signaling pathway
Objective To explore the inhibition of the proliferation of vulvar squamous cell carcinoma (VSCC) by astragaloside IV. Methods MTT examined the cell proliferation of VSCC. Flow cytometry analyzed cell cycle and apoptosis. Western blot assay detected the expression of some relevant proteins. Results AS‐IV reduced the proliferation of SW962 cells in a concentration‐ and time‐dependent manner, induced cell‐cycle arresting in G0/G1 phase, as demonstrated by the up‐regulation of P53 and P21 expression, and the down‐regulation of cyclin D1 expression. AS‐IV enhanced the expression of Bax and cleaved‐caspase 3, and suppressed Bcl‐2 and Bcl‐xl expression, which resulted in apoptosis increased. Furthermore, the expression of Beclin‐1 and LC3‐B was upregulated and that of P62 was downregulated, which suggested that AS‐IV could increase the incidence of autophagy in SW962 cells. After inhibiting autophagy by 3‐methyladenine, cell apoptosis decreased upon AS‐IV treatment. Similarly, TGF‐β1 stimulated SW962 cells, cell proliferation enhanced, and the expression of TGF‐βRII and Smad4 was decreased. Furthermore, the expression of proteins that promote apoptosis and autophagy decreased. After AS‐IV treatment, the expression levels of the above proteins exhibited the opposite effect. Conclusion AS‐IV inhibits cell proliferation and induces apoptosis and autophagy through the TGF‐β/Smad signaling pathway in VSCC.